Beijing Shuoxing Biomedical Technology

Beijing Shuoxing Biomedical Technology (Shuoxing Bio) is a clinical-stage biopharmaceutical company dedicated to developing next-generation multi-specific antibody therapeutics. Headquartered in Beijing, the company leverages its proprietary Star-Body platform, which utilizes nanobody (VHH) technology to engineer complex biologics with high specificity and potency. Shuoxing Bio's research focuses primarily on oncology and immunology, aiming to address unmet medical needs in patients with refractory or metastatic cancers. Its lead program, SSB-010, is a bifunctional fusion protein targeting PD-L1 and TGF-beta that has entered clinical trials in both China and the United States. The company's modular design strategy enables the efficient production of bispecific and trispecific antibodies with favorable safety profiles. Supported by leading healthcare investors, Shuoxing Bio continues to expand its pipeline of innovative immunotherapy candidates.